宫颈人乳头瘤病毒感染现状及其疫苗的应用现状(3) - 中国疫苗和免疫杂志社投稿

来稿应自觉遵守国家有关著作权法律法规，不得侵犯他人版权或其他权利，如果出现问题作者文责自负，而且本刊将依法追究侵权行为给本刊造成的损失责任。本刊对录用稿有修改、删节权。经本刊通知进行修改的稿件或被采用的稿件，作者必须保证本刊的独立发表权。一、投稿方式： 1、请从我刊官网直接投稿。 2、请从我编辑部编辑的推广链接进入我刊投审稿系统进行投稿。二、稿件著作权： 1、投稿人保证其向我刊所投之作品是其本人或与他人合作创作之成果，或对所投作品拥有合法的著作权，无第三人对其作品提出可成立之权利主张。 2、投稿人保证向我刊所投之稿件，尚未在任何媒体上发表。 3、投稿人保证其作品不含有违反宪法、法律及损害社会公共利益之内容。 4、投稿人向我刊所投之作品不得同时向第三方投送，即不允许一稿多投。 5、投稿人授予我刊享有作品专有使用权的方式包括但不限于：通过网络向公众传播、复制、摘编、表演、播放、展览、发行、摄制电影、电视、录像制品、录制录音制品、制作数字化制品、改编、翻译、注释、编辑，以及出版、许可其他媒体、网站及单位转载、摘编、播放、录制、翻译、注释、编辑、改编、摄制。 6、第5条所述之网络是指通过我刊官网。 7、投稿人委托我刊声明，未经我方许可，任何网站、媒体、组织不得转载、摘编其作品。

宫颈人乳头瘤病毒感染现状及其疫苗的应用现状(3)

作者:

关键词:

摘要：

3 展望

人乳头瘤病毒与宫颈癌及其癌前病变的关系已趋于明了，而HPV基因分型在不同地域、不同类型的宫颈病变有不同的分布特点，通过对HPV基因型分布特点进行研究，有助于科学制定个体化预防及诊疗方案。

人类乳头瘤病毒(HPV)疫苗问世10年来，在预防约95%的接种人群持续感染癌前病变方面显示出了有效性和安全性。并且2020年11月17日，世卫组织正式启动加速消除宫颈癌的全球战略，该战略的目标是2030年所有国家实现90%的HPV疫苗接种覆盖率、70%的筛查覆盖率和90%的治疗覆盖率[46]。故HPV疫苗的更广泛甚至全面的应用有望在各国的努力下获得实现。目前治疗性疫苗还在临床试验研究阶段，仍有很多困难需要解决，但我们有理由相信，随着各国研究人员的努力，宫颈癌疫苗会不断有新的突破，终将踏上新的里程，治疗性疫苗有望成为治疗并清除宫颈癌的疫苗。

[1]Freddie Bray BSc, MSc, PhD, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians,2018,68(6):394-424.

[2]Harald zur Hausen. Papillomaviruses and cancer: from basic studies to clinical application[J]. Nature Reviews Cancer,2002,2(Suppl. 5):342.

[3]Groves Ian J,Coleman Nicholas. Pathogenesis of human papillomavirus-associated mucosal disease[J]. The Journal of pathology,2015,235(4):527-538.

[4]John Doorbar,WimQuint,Lawrence Banks, et al. The Biology and Life-Cycle of Human Papillomaviruses[J]. Vaccine,2012,30:F55-F70.

[5]Harald zur Hausen. Papillomaviruses and cancer: from basic studies to clinical application[J]. Nature Reviews Cancer,2002,2(Suppl. 5):342.

[6]Harald zur Hausen. Papillomaviruses in the causation of human cancers — a brief historical account[J]. Virology,2008,384(2):260-265.

[7]David Forman,Catherine de Martel,Charles J. et al. Global Burden of Human Papillomavirus and Related Diseases[J]. Vaccine,2012,30:F12-F23.

[8]Dunne EF, Park IU. HPV and HPV-associated diseases[J]. Dis Clin North Am,2013,27(4):765-778.

[9]Nagayasu, Egawa, Kiyofumi, et al. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia[J]. Viruses,2015,7(7):3863-3890.

[10]Choi YounJin,Park Jong Sup. Clinical significance of human papillomavirus genotyping[J]. Journal of gynecologic oncology,2016,27(2) :e21.

[11]VéroniqueBouvard,RobertBaan,KurtStraif, et al. A review of human carcinogens—Part B: biological agents[J]. Lancet Oncology,2009,10(4):321-322.

[12]Khan Michelle J,Castle Philip E,Lorincz Attila T, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice[J]. Journal of the National Cancer Institute,2005,97(14):1072.

[13]Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO/IARC information Centre on papillomavirus and cancer (HPV information Centre).Human papillomavirus and related diseases in the world.[EB/OL].[2017-07-20].

[14]Silvia de Sanjose,Wim GV Quint,LaiaAlemany, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncology,2010,11(11):1048-1056.

[15]Bruni Laia,DiazMireia,CastellsaguéMireia, et al. Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings[J]. The Journal of Infectious Diseases,2010,202(12):1789-1799.

[16]Serrano Beatriz,BrotonsMaría,BoschFrancesc Xavier, et al. Epidemiology and burden of HPV-related disease[J]. Best practice & research. Clinical obstetrics & gynaecology,2018,47:14-26.

[17]Peng Guan,Rebecca Howell-Jones,Ni Li, et al. Human papillomavirus types in 115,789 HPV-positive women: A metaanalysis from cervical infection to cancer[J]. International Journal of Cancer,2012,131(10):2349-2359.

[18]李霓,代敏.中国妇女人乳头状瘤病毒感染的多中心横断面研究[J].疾病控制杂志,2008,12(5):411-415.

[19]Smith Jennifer S,LindsayLisa,Hoots Brooke, et al. Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update[J]. International journal of cancer,2007,121(3):621-632.

[20]Gary Clifford,SilviaFranceschi,Mireia Diaz, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases[J]. Vaccine,2006,24(Suppl 3):S3/26-34.

[21]鲍彦平,李霓,王鹤,等.中国妇女子宫颈人乳头瘤病毒型别分布的Meta分析[J].中华流行病学杂志,2007,28(10):941-946.

[22]Tiffany A. Suragh,PaigeLewis,Jorge Arana, et al. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS),2009-2017[J]. British Journal of Clinical Pharmacology,2018,84(12):2928-2932.

[23]Giulia Bonaldo,AlbertoVaccheri,OttavioD'Annibali, et al. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017[J]. British Journal of Clinical Pharmacology,2019,85(3):634-643.

文章来源：《中国疫苗和免疫》网址: http://www.zgymhmy.cn/qikandaodu/2021/0709/1742.html